04th week of 2011 patent applcation highlights part 48 |
Patent application number | Title | Published |
20110021541 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA - Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed. | 2011-01-27 |
20110021542 | Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder - The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder. | 2011-01-27 |
20110021543 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS PESTICIDES - Novel N-aryl substituted heteroindole compounds, processes for their manufacture, veterinary compositions containing such compounds, and methods of controlling ectoparasites are provided. The compounds are believed effective in the control of ectoparasites on warm-blooded productive livestock and domestic animals. | 2011-01-27 |
20110021544 | HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE - Disclosed is a compound of formula (I): | 2011-01-27 |
20110021545 | NOVEL PREPARATION FOR EXTERNAL USE - A compound represented by the formula (I), salt thereof, or hydrate thereof has an excellent anti-pruritic effect and an excellent effect in terms of metabolism. The topical formulation of the present invention has excellent skin absorption properties of the compound represented by the formula (I), salt thereof, or hydrate thereof. Furthermore, the topical formulation of the present invention is excellent in stability because ingredients are hardly bled after long-term storage. | 2011-01-27 |
20110021546 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 2011-01-27 |
20110021547 | Substantially Pure and a Stable Crystalline Form of Bosentan - Described is a highly stable crystalline form of bosentan having a water content in the range of about 3-4% by weight, based on the total weight of the bosentan, (bosentan crystalline form A5), a process for preparation thereof, and pharmaceutical compositions comprising the bosentan crystalline form A | 2011-01-27 |
20110021548 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF - The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity. | 2011-01-27 |
20110021549 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS - The present invention relates to substituted benzofused derivatives, which can he used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them. | 2011-01-27 |
20110021550 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation - Compounds of formula (I) wherein the groups R1 to R8 have the meanings indicated in the description, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof have valuable pharmacological properties, which make them useful for the treatment of cardiovascular and related disorders. | 2011-01-27 |
20110021552 | Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Depression, Anxiety, and Neurodegenerative Disorders - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 2011-01-27 |
20110021553 | IMMUNOSUPPRESSIVE MACROLIDE POWDER FOR ORAL SUSPENSION - The present invention describes pharmaceutical compositions that comprise a tacrolimus powder for oral suspension that exhibits great stability as a powder for suspension and also, once prepared, as the extemporaneous suspension, without the formation of cake-like clusters, same having a satisfactory flavour and a pleasant aroma. The invention also describes the method for preparing the pharmaceutical compositions, same being a dry method that comprises mixing tacrolimus and pre-sieved pharmaceutically acceptable carriers for a suitable length of time, and the use of the pharmaceutical compositions for treating and preventing rejection of transplanted organs and atopic dermatitis. | 2011-01-27 |
20110021554 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS - An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin- | 2011-01-27 |
20110021555 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORTER DOSING REGIMENS FOR TREATING ACTINIC KERATOSES - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described. | 2011-01-27 |
20110021556 | PYRROLIDINYL DERIVATIVES AND USES THEREOF - The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds. | 2011-01-27 |
20110021557 | Deuterium-enriched pyridinonecarboxamides and derivatives - The present invention relates to deuterium-enriched pyridinone carboxamides and their derivatives of the formula I, and pharmaceutically acceptable salts thereof, | 2011-01-27 |
20110021558 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS - A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. | 2011-01-27 |
20110021559 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 2011-01-27 |
20110021560 | Compositions And Methods For Regulating Chondrocyte Proliferation In Bone Disorders - The present invention is related to the field of cartilage physiology, repair, and regeneration. In particular, the invention contemplates a treatment for bone healing disorders, especially those related to the articular joints and bone, by upregulating chondrocyte proliferation. For example, inhibition of cysteinyl leukotriene activity on chondrocytes by using cysteinyl leukotriene-1 receptor antagonists may be useful in preventing and treating bone healing disorders. This invention also relates to other physiologic conditions which are influenced by chondrocyte activity, including pediatric long bone growth and neoplastic conditions involving cells of chondrogenic origin | 2011-01-27 |
20110021561 | QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USES THEREOF - The present invention discloses a quinoline compound represented by the formula A or pharmaceutically acceptable solvate, optical isomer or polymorph thereof, | 2011-01-27 |
20110021562 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS - The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors. | 2011-01-27 |
20110021563 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF - The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions. | 2011-01-27 |
20110021564 | METHOD OF TREATING BINGE EATING DISORDER AND OBESITY RESULTING FROM BINGE EATING BEHAVIOR - The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention. | 2011-01-27 |
20110021565 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS - The invention relates to a compound of formula | 2011-01-27 |
20110021566 | GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS - Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction. | 2011-01-27 |
20110021567 | PREPARATION OF LENALIDOMIDE - Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide. | 2011-01-27 |
20110021568 | TUBULYSIN D ANALOGUES - The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The compounds of the invention are highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D. | 2011-01-27 |
20110021569 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2011-01-27 |
20110021570 | PYRIDONE GLUCOKINASE ACTIVATORS - Provided herein are compounds of the formula (I): | 2011-01-27 |
20110021571 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE - The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof. | 2011-01-27 |
20110021572 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES - The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2011-01-27 |
20110021573 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 2011-01-27 |
20110021574 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME - Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to anti-cancer compounds, synthesis thereof, and methods of using same. Disclosed herein are various heterocyclic compounds and methods of using the novel anti-cancer compounds to inhibit the growth of a cancer cell, for instance a leukemia, non-small cell lung, central nervous system (CNS), skin, ovarian, renal, prostate, breast, or colon cancer cell. Other embodiments include methods of treating cancer in a subject, such as using the disclosed heterocyclic anti-cancer agents. | 2011-01-27 |
20110021575 | PENETRATION ENHANCERS FOR INSECTICIDAL AGENTS - Polyalkylene oxide derivates of the formula (I), | 2011-01-27 |
20110021576 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 2011-01-27 |
20110021577 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS - The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated. | 2011-01-27 |
20110021578 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine - Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R | 2011-01-27 |
20110021579 | PERITONEUM PROTECTING AGENT - It is an objective of the present invention to provide a novel peritoneal membrane protecting agent which can effectively suppress deterioration of peritoneal functions in long-term peritoneal dialysis (PD) patients and the like. The present invention provides a peritoneal membrane protecting agent comprising a pyridoxine or a salt thereof, as an active ingredient. | 2011-01-27 |
20110021580 | PLANT DISEASE CONTROL COMPOSITION - A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect. | 2011-01-27 |
20110021581 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST - The present invention relates to a dosing regimen for a selective S1P | 2011-01-27 |
20110021582 | BENZOPHENONE THIAZOLE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE AND METHOD FOR PRODUCING THE SAME - Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone thiazole derivatives inhibit formation of microtubules and eliminate actively proliferating cells of malignant tumors to control general cell proliferation. In formula 1, R, R | 2011-01-27 |
20110021583 | ENHANCED TRANSMUCOSAL COMPOSITION AND DOSAGE FORM - The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity-facilitated transmucosal transport of said active compound across the mucosal tissue. The invention also provides a solid transmucosal dosage form containing the composition, as well as a method of treatment comprising administering the same. In one embodiment, the active compound is a triptan compound, e.g., sumatriptan and zolmitriptan. | 2011-01-27 |
20110021584 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 2011-01-27 |
20110021585 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula: | 2011-01-27 |
20110021586 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS - There is provided a compound of Formula I | 2011-01-27 |
20110021587 | METHODS OF REDUCING OR ELIMINATING BACTERIA IN CONSUMABLE EGGS - Methods are provided for reducing or eliminating bacteria such as | 2011-01-27 |
20110021588 | SUBLINGUAL DEXMEDITOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF - Analgesic sublingual formulations of dexmedetomidine and methods of use thereof are provided for use in the prevention, treatment and management of pain and other conditions. | 2011-01-27 |
20110021589 | IMIDAZOLIC COMPOUNDS AND USE THEREOF AS ALPHA-2 ADRENERGIC RECEPTORS - The invention provides methods of treating a memory deficiency in a subject in need of such treatment, where the methods comprise administering to a subject an effective amount of a compound of formula (1): | 2011-01-27 |
20110021590 | AMINOPYRROLIDINONE DERIVATIVES AND USES THEREOF - The present invention provides compounds of formula I: | 2011-01-27 |
20110021591 | PHENYLBUTAZONE CARRIER FORMULATION SHOWING INCREASED BIOACTIVITY IN ANIMALS - An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine. | 2011-01-27 |
20110021592 | ORGANIC NANOPARTICLES OBTAINED FROM MICROEMULSIONS BY SOLVENT EVAPORATION - The present invention provides a process for preparing a redispersible powder of nanoparticles of a water-insoluble organic compound, the process including the steps of: (i) preparing an oil-in-water microemulsion comprising a water-insoluble organic compound, a volatile water-immiscible organic solvent, water, and at least one surfactant; and (ii) removing the volatile water-immiscible organic solvent and the water so as to form the redispersible powder comprising said nanoparticles, wherein the nanoparticle are in a particulate form, and wherein the solubility of the water-insoluble organic compound is at least about 5 times greater than the solubility of the water-insoluble organic compound in unprocessed form. Step (i) can further include the addition of co-solvent or polymer. The water-insoluble organic compound can be a pharmaceutically active agent (in particular a statin), a cosmetic active agent, an anti oxidant, a preservative, a colorant, a food additive, an agriculturally active compound and a fragrance. | 2011-01-27 |
20110021593 | NOVEL CRYSTAL OF SUBSTITUTED PHENYLALKANOIC ACID ESTER AND PROCESS FOR PRODUCING THE SAME - [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. | 2011-01-27 |
20110021594 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof - The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production. | 2011-01-27 |
20110021595 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises mixtures of carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye and improve visual acuity of the users. | 2011-01-27 |
20110021596 | Topical therapy for migraine - The invention is directed to formulations and methods of treating a migraine and/or cluster headache with a serotonin agonist, pharmaceutically acceptable salt thereof, or derivative thereof. | 2011-01-27 |
20110021597 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 2011-01-27 |
20110021598 | CONTROLLED RELEASE FORMULATIONS - The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme. | 2011-01-27 |
20110021599 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH - This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analogue or mimetic thereof; and methods of testing for AGA and evaluating therapeutic methods thereof, comprising measuring PGD2 levels. | 2011-01-27 |
20110021600 | NOVEL NUCLEIC ACID - According to the present invention, it possible to provide a novel nucleic acid, a vector that expresses the nucleic acid, a screening method for a substance that controls the nucleic acid, a method of detecting the expression and a mutation of the nucleic acid, and a diagnostic method or therapeutic method for a disease caused by an abnormality of mesenchymal stem cells, mast cells or the like, or a disease caused by a cell proliferation abnormality, such as cancer. | 2011-01-27 |
20110021601 | COMPOSITION CONTAINING MICRORNA-21 INHIBITOR FOR ENHANCING RADIATION SENSITIVITY - Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma. | 2011-01-27 |
20110021602 | GRAFT POLYMERS FOR ENHANCED INTRACELLULAR DELIVERY OF ANTISENSE MOLECULES - Innovative graft polymers designed for the efficient delivery of antisense molecules into biological cells and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such polymers may comprise an anionic graft polymer comprising an anionic polymer backbone with pendant carboxylic acid groups and pendant chains comprising amphipathic or hydrophilic polymers covalently bonded to a portion of said pendant carboxylic acid groups. Antisense molecule delivery vectors comprising such polymers in combination with cationic agents for delivery of antisense molecules are also disclosed. | 2011-01-27 |
20110021603 | TRPM-2 Antisense Therapy - It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed. | 2011-01-27 |
20110021604 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA - This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures. | 2011-01-27 |
20110021605 | MEANS AND METHODS FOR THE SPECIFIC INHIBITION OF GENES IN CELLS AND TISSUE OF THE CNS AND/OR EYE - Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye, wherein a composition comprising one or more doubled stranded oligoribonucleotides (dsRNA) is introduced into the cell, tissue or organism outside the blood-brain or blood-retina barriers. Furthermore, a method for the identification and validation of the function of a gene is provided, wherein the method provides a test cell, test tissue or test organism, which allow information to be gained on the function of the target gene. In addition, compositions and kits are described useful for those methods. In particular, components and methods for the diagnostic use and/or therapy of disorders related to the CNS and/or eye are provided which are based on RNA interference. | 2011-01-27 |
20110021606 | RNAi Modulation of RSV, PIV and Other Respiratory Viruses and Uses Thereof - The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV or PIV mRNA levels, RSV or PIV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses. | 2011-01-27 |
20110021607 | Methods and Compositions Relating to Carcinoma Stem Cells - MicroRNA markers of breast cancer stem cells (BCSC) are provided herein. The markers are polynucleotides that are differentially expressed in BCSC as compared to normal counterpart cells. Uses of the markers include use as targets for therapeutic intervention; as targets for drug development, and for diagnostic or prognostic methods relating to breast cancer and BCSC cell populations. BCSCs have the phenotype of having lower expression of certain miRNAs compared to normal breast epithelial cells, or to cancer cells that are not cancer stem cells. | 2011-01-27 |
20110021608 | METHODS FOR NUCLEIC ACID TRANSFER INTO CELLS - The present invention provides methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or expression in cells in vitro and in vivo for research and gene therapy applications. | 2011-01-27 |
20110021609 | MicroRNA Signatures Associated with Cytogenetics and Prognosis in Acute Myeloid Leukemia (AML) and Uses Thereof - Methods and compositions utilizing an miRNA signature for the diagnosis, prognosis and/or treatment of leukemia associated diseases, particularly acute myeloid leukemia, are disclosed. | 2011-01-27 |
20110021610 | AROMATIC PRENYLTRANSFERASE FROM HOP - Nucleic acid molecules from hop ( | 2011-01-27 |
20110021611 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 5A - The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a. Conclusion: The developed 5a/2a viruses provide a robust in vitro tool for research in HCV genotype 5, including vaccine studies and functional analyses of an increasingly important genotype in South Africa and Europe. | 2011-01-27 |
20110021612 | NK1 FRAGMENT OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AND VARIANTS THEREOF, AND THEIR USE - The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure. | 2011-01-27 |
20110021613 | PLANTS EXTRACTS FOR USE IN BRAIN MODULATION - Compounds obtainable from plants, e.g. of the genus | 2011-01-27 |
20110021614 | USE OF SILYMARIN AND SILYBIN IN THE TREATMENT OF NEURAL INJURY - The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin. | 2011-01-27 |
20110021615 | METHOD OF PROTECTING PLANT(S) AND A PROCESS THEREOF - The present invention relates to a method of treating plant(s) against larval pests by the use of terreulactone. It also relates to a process for producing meroterpenoid from fungus | 2011-01-27 |
20110021616 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF - Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′, 5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide. | 2011-01-27 |
20110021617 | Medicinal Acidic Cannabinoids - The invention relates to an acidic cannabinoid for medical use and to a | 2011-01-27 |
20110021618 | METHODS OF TREATING FIBROTIC DISORDERS - Described herein are compositions and methods for preventing and/or treating fibrotic disorders employing one or more benzo[c]chromen-6-one derivatives. | 2011-01-27 |
20110021619 | EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE - To increase a tissue regeneration ability of a living body such as a collagens production ability of fibroblast in the dermis in a skin defect area typified by a large wrinkle or wound, a flavanone derivative such as farrerol is used as an active ingredient of an external preparation for skin. Further, to efficiently screen a substance having an excellent effect on promoting wound healing, the remodeling action of collagen fiber bundle is tested by using skin wound model. | 2011-01-27 |
20110021620 | USE OF TEA POLYPHENOLS IN PREPARING MEDICAMENTS FOR PREVENTION OR TREATMENT OF TUMORS - Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors is provided. The tea polyphenols are tea extracts comprising EGCG, EGC, and ECG, or Tegreen 97®, a green tea capsule of PHARMANEX, INC. | 2011-01-27 |
20110021621 | Drug for treating circulatory insufficiency - The present invention relate to a drug for treating circulatory insufficiency containing a benzopyran derivative represented by the following general formula (I): | 2011-01-27 |
20110021622 | Stabilized Synthetic Brood Pheromone and Race-Specific Ratios of Components for Manipulating the Behavior and Physiology of Honey Bees - This invention relates to a 10-component stabilized synthetic honey bee brood pheromone and methods of stabilizing said pheromone by adding one or more antioxidants, thereby enabling the production and sustained use of commercial products based on that pheromone. The 11-component stabilized pheromone composition formed by adding the antioxidant tertiary-butyl hydroquinone to a synthetic blend of ethyl linoleate, ethyl linolenate, ethyl oleate, ethyl palmitate, ethyl stearate, methyl linoleate, methyl linolenate, methyl oleate, methyl palmitate and methyl stearate can be used in generic or race-specific ratios to manipulate the behavior and improve the performance of worker honey bees, resulting in overall increased vigor of the hive. | 2011-01-27 |
20110021623 | SYSTEM AND METHODS OF MELANOMA PREVENTION - Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to prevent damage and/or death of melanocytes. The inhibitor agent can be applied to the skin or ingested. | 2011-01-27 |
20110021624 | Alpha-Amino-N-Substituted Amides, Pharmaceutical Composition Containing Them and Uses Thereof - Disclosed are a series of α-amino-N-substituted amide compounds having a structure of the following formula, the pharmaceutically acceptable salts thereof, and the pharmaceutical composition comprising the same. The α-amino-N-substituted amide compounds or the pharmaceutically acceptable salts thereof according to the present invention have anti-tumor and/or anti-cancer activities in vivo and in vitro, can effectively depress the growth of various tumor cells and/or cancer cells, and thus can be used in preparing drugs for treating tumors and/or cancers. | 2011-01-27 |
20110021625 | NEURONAL CELL DEATH INHIBITOR - There is provided a neuronal cell death inhibitor having a high efficacy. A neuronal cell death inhibitor comprising a compound of general formula (1) below: | 2011-01-27 |
20110021626 | ENCAPSULATION OF VITAMIN C INTO WATER SOLUBLE DENDRIMERS - The invention relates to a conjugated dendrimer that comprises at least one water-soluble dendrimer and at least one vitamin C molecule. The conjugated dendrimer can be used e.g. for preparing cosmetic or pharmaceutical compositions. The dendrimers have a good vitamin C load capacity and are biocompatible. | 2011-01-27 |
20110021627 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST - There is provided a nitrile compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein m represents in integer of 0 to 4; n represents an integer of 1 to 4; q represents an integer of 0 to 4; Q represents a C1-C4 fluoroalkyl group; Z represents an optionally substituted C2-C6 alkynyl group or a ═N—OR | 2011-01-27 |
20110021628 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 2011-01-27 |
20110021629 | IRON PREPARATION SUITABLE FOR PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION THEREOF - New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications. | 2011-01-27 |
20110021630 | METHOD FOR TREATING WOUNDS BY ADMINISTERING FULLERENES - Disclosed herein are methods for treating wounds. In one embodiment, the method comprises: administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene of the formula Z | 2011-01-27 |
20110021631 | Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms - A process is described for the preparation of a pharmaceutical comprising an active pharmaceutical ingredient capable of existing in multiple polymorphic forms, wherein the process comprises a step of preparation of a wet phase comprising the active pharmaceutical ingredient and microcrystalline cellulose and a liquid, wherein in the wet phase has a weight ratio of active pharmaceutical ingredient to microcrystalline cellulose above 1.0 or a weight ratio of active pharmaceutical ingredient to liquid above 1.0. | 2011-01-27 |
20110021632 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION - The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system. | 2011-01-27 |
20110021633 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 2011-01-27 |
20110021634 | PROCESSES FOR PREPARING METFORMIN HYDROCHLORIDE - A process for reducing dimethylamine content in metformin hydrochloride is disclosed. The process comprises:
| 2011-01-27 |
20110021635 | RBM3 AS A MARKER FOR BREAST CANCER PROGNOSIS - The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in at least part of said sample, and determining a sample value corresponding to said evaluated amount; comparing the sample value obtained with a reference value associated with said reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said subject is better than said reference prognosis. | 2011-01-27 |
20110021636 | METHOD FOR CRYSTALLIZATION OF 2-AMINO-2-[2-[4-(3-BENZYLOXYPHENYLTHIO)-2-CHLOROPHENYL]-ETHYL]-1,3-PROPAN- EDIOL HYDROCHLORIDE - A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding hydrochloric acid to the resulting solution with stirring, to crystallize the hydrochloride of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]ethyl]-1,3-propanediol. | 2011-01-27 |
20110021637 | XANTHOHUMOL AND TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT - Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops. | 2011-01-27 |
20110021638 | MODULATION OF INFLAMMATION BY HOPS FRACTIONS AND DERIVATIVES - A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandin selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. | 2011-01-27 |
20110021639 | Microbially stable dispersion medium for emulsions - The present invention relates to novel microbial stable emulsions advantageously utilizing dispersion media characterized by lower water activity and advantageously utilizing dispersants which exhibit high water binding capacity and which exhibit characteristics which provide for steric stabilization and charge distribution (zeta potential) in relation to the dispersed phase, and methods of using the same. | 2011-01-27 |
20110021640 | Mechanism-based biochemical standardization of resveratrol products and their uses thereof - The present invention pertains to methods (a) Inhibition of adenosine deaminase by resveratrol products including botanical extracts containing resveratrol and/or oxyresveratrol; (b) Biochemical Standardization of these products as Enzyme Inhibitory Units (EIU) per mg or gram; and (c) Their uses thereof. | 2011-01-27 |
20110021641 | SUSPENSION FORMULATION FOR CARBON ADSORBENTS - The invention relates to an aqueous suspension formulation comprising a coarsely particulate carbon adsorbent which is suitable for binding and eliminating harmful substances from the gastrointestinal tract, and a water-soluble or water-dispersible structure-forming agent and a humectant. | 2011-01-27 |